Herantis Pharma reported positive top-line results from the second part of its Phase Ib trial, evaluating lead candidate HER-096 in Parkinson’s disease (PD) patients, meeting both the primary and secondary endpoints. Both 200mg and 300mg twice-weekly doses (administered for four weeks) were shown t
